Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”
2016-11-15

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patientJournal of HepatologyVol. 65Issue 4PreviewCholangiocarcinomas (CCA), heterogeneous malignant epithelial tumors originating from hepatic ductal cells, are typically diagnosed in a late stage and have a particularly poor prognosis [1]. CCA are rare in the Western world (0.5–1.5/100,000 persons), while they are the second most frequent primary liver cancer worldwide [2]. Risk factors include liver cirrhosis, viral hepatitis, hepatobiliary flukes and primary sclerosing cholangitis [1]. A recent systematic meta-analysis of 4,756 patients with intrahepatic cholangiocarcinoma (iCCA) reported 5-year survival rates between 5 and 56% and a median survival of 28 months [3]. Full-Text PDF Open Access Unfortunately, an error was introduced during the redrawing of the Fig. 3. The error concerned the labelling and orientation of Fig. 3B, which was not correctly reflected in the respective figure legend. Please find the corrected legend and Fig. 3 below. During further scrutiny, the authors noticed a few minor typographical errors in the published article. The corrections are as follows: Page 850 – Materials and methods Next-generation-sequencing As part of a research project (IndividuaLIVER, approved by the Institutional Review Board at the University Hospital of Tübingen), WES of tumor and normal tissue was performed for L06/10, L04/12 and P03/13 (Fig. 1). In addition, the transcriptome of tumor tissue of L06/12 and P03/13 was sequenced. Should have read: As part of a research project (IndividuaLIVER, approved by the Institutional Review Board at the University Hospital of Tübingen), WES of tumor and normal tissue was performed for L06/10, L04/12 and P03/13. In addition, the transcriptome of tumor tissue of L06/10 and P03/13 was sequenced. Mass spectrometry HLA ligands were immunoprecipitated from cryopreserved tumor tissues and liver tissue (L03/10) as previously described [12] using the pan-HLA class I antibody, W6/32 (manufactured in-house). Should have read: HLA ligands were immunoprecipitated from cryopreserved tumor tissues and liver tissue (L06/10) as previously described [12] using the pan-HLA class I antibody, W6/32 (manufactured in-house). T cell in vitro immunomonitoring Responses to HLA class I peptides were monitored by IFN-γ ELISPOT and HLA-peptide multimer staining, while responses to HLA class II peptides and RGS-5 peptide were determined by IFN-γ ELISPOT and ICS (for IFN-γ, TNF-β, IL-2 and IL-10) (all techniques are elaborated in the Supplementary materials and methods). Should have read: Responses to HLA class I peptides were monitored by IFN-γ ELISPOT and HLA-peptide multimer staining, while responses to HLA class II peptides and RGS-5 peptide were determined by IFN-γ ELISPOT and ICS (for IFN-γ, TNF-α, IL-2 and IL-10) (all techniques are elaborated in the Supplementary materials and methods). Page 851 (Table 1) The column heading P03/12 in the published version, should read P03/13. Page 852 (Results) Vaccination, further clinical course and immunomonitoring; 4th paragraph T cell cytokine response was detected against CCND1 by IFN-γ ELISPOT (Fig. 3A) and was confirmed to be a CD4+ response by intracellular cytokine staining (ICS) (Fig. 3B left lower panel). Should have read: T cell cytokine response was detected against CCND1 by IFN-γ ELISPOT (Fig 3A) and was confirmed to be a CD4+ response by intracellular cytokine staining (ICS) (Fig. 3B top panel). Both the journal and the authors apologise for any inconvenience that these errors may have caused.